ArticleBMC urology2026
Diagnostic value of PSA-based markers in prostate cancer: a retrospective analysis stratified by body mass index.
Article in BMC urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveBody mass index (BMI) influences the accuracy of prostate-specific antigen (PSA) in prostate cancer (PCa) diagnostic performance. This study investigates the effect of BMI on conventional PSA-based markers and evaluates a novel age-adjusted PSA density parameter (A-PSAD) to optimize diagnostic performance strategies across different BMI groups.
resultsThe cohort comprised 307 low-BMI (91 PCa, 216 benign) and 356 high-BMI (109 PCa, 247 benign) patients. In the low-BMI group, A-PSAD yielded the highest diagnostic efficacy (AUC = 0.714), outperforming PSAD (0.685) and total PSA (TPSA, 0.588). In the high-BMI group, A-PSAD also demonstrated superior performance (AUC = 0.793) compared to PSAD (0.774) and TPSA (0.613). A-PSAD's overall diagnostic value was significantly higher than conventional markers across both groups (P < 0.01). Furthermore, LASSO regression identified four optimal predictive variables for the low-BMI group and seven for the high-BMI group; A-PSAD consistently emerged as a core independent predictor in both.
conclusionBMI significantly modulates the diagnostic efficacy of PCa diagnostic performance indicators. A-PSAD demonstrates robust, superior diagnostic value across varying BMI categories, serving as a promising primary diagnostic performance tool to optimize individualized pre-biopsy risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.